Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Docetaxel|DRUG: Epirubicin|DRUG: Epirubicin|DRUG: Docetaxel
Sponsor: Hellenic Oncology Research Group
Collaborators: University Hospital of Crete